Prader-Willi Syndrome (PWS)

IRB
CHLA-19-00013
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) with Long Term Follow-Up: CARE-PWS

This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.

Study Details
Clinical Trials Government Identifier
NCT03649477
Keywords
Prader-Willi Carbetocin, PWS, Carbetocin, LV-101
Eligibility
7 to 18 years of age with genetically confirmed PWS
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Yareli Pineda
Contact Email
ypineda@chla.usc.edu